BioNexus Gene Lab (BGLC) Enterprise Value (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Enterprise Value data on file, last reported at -$4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 89.76% year-over-year to -$4.0 million; the trailing twelve-month figure through Mar 2026 stood at -$4.0 million (down 89.76% YoY), and the FY2025 full-year result was -$4.0 million, up 28.89% from the prior year.
• Enterprise Value rose to -$4.0 million in Q1 2026, from -$4.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$1.3 million in Q2 2022 to a low of -$5.8 million in Q1 2024.
• A 5-year average of -$3.2 million and a median of -$2.9 million in 2025 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value tumbled 221.75% in 2023 and surged 64.17% in 2025, its largest moves.
• Tracing BGLC's Enterprise Value over 5 years: stood at -$2.1 million in 2022, then slumped by 113.21% to -$4.5 million in 2023, then dropped by 25.75% to -$5.7 million in 2024, then climbed by 28.89% to -$4.0 million in 2025, then rose by 1.85% to -$4.0 million in 2026.
• Business Quant data shows BGLC's Enterprise Value at -$4.0 million in Q1 2026, -$4.0 million in Q4 2025, and -$2.9 million in Q3 2025.